CRNX

Company Overview — What Does Crinetics Pharmaceuticals, Inc. Do?

Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist that has completed phase III clinical trial for the treatment of acromegaly, as well as completed phase II clinical trial to treat carcinoid syndrome and nonfunctional neuroendocrine tumors (NETs). The company is also developing CRN04777, an oral selective nonpeptide somatostatin type 5 receptor agonist, which is in phase I clinical trial for the treatment of congenital hyperinsulinism; and CRN04894, an oral adrenocorticotrophic hormone antagonist that is in phase I clinical trial for the treatment of Cushing's and congenital adrenal hyperplasia diseases. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California. Crinetics Pharmaceuticals, Inc. (CRNX) is classified as a mid-cap stock in the Healthcare sector, specifically within the Pharmaceutical Products industry. The company is led by CEO Scott R. Struthers and employs approximately 210 people. With a market capitalization of $3.8B, CRNX is one of the notable companies in the Healthcare sector.

Crinetics Pharmaceuticals, Inc. (CRNX) Stock Rating — Reduce (April 2026)

As of April 2026, Crinetics Pharmaceuticals, Inc. receives a Reduce rating with a composite score of 33.3/100 and 2 out of 5 stars from the Blank Capital Research quantitative model.CRNX ranks #3,350 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, Crinetics Pharmaceuticals, Inc. ranks #509 of 838 stocks, placing it in the lower half of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

CRNX Stock Price and 52-Week Range

Crinetics Pharmaceuticals, Inc. (CRNX) currently trades at $39.41. The stock lost $0.23 (0.6%) in the most recent trading session. The 52-week high for CRNX is $57.99, which means the stock is currently trading -32.0% from its annual peak. The 52-week low is $24.10, putting the stock 63.5% above its annual trough. Recent trading volume was 474K shares, suggesting relatively thin trading activity.

Is CRNX Overvalued or Undervalued? — Valuation Analysis

Crinetics Pharmaceuticals, Inc. (CRNX) carries a value factor score of 22/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The price-to-book ratio stands at 4.05x, versus the sector average of 2.75x. The price-to-sales ratio is 2620.02x, compared to 1.66x for the average Healthcare stock.

At current multiples, Crinetics Pharmaceuticals, Inc. trades at a premium to most Healthcare peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.

Crinetics Pharmaceuticals, Inc. Profitability — ROE, Margins, and Quality Score

Crinetics Pharmaceuticals, Inc. (CRNX) earns a quality factor score of 20/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is -42.3%, compared to the Healthcare sector average of -43.5%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at -37.2% versus the sector average of -33.1%.

On a margin basis, Crinetics Pharmaceuticals, Inc. reports gross margins of 86.0%, compared to 71.5% for the sector. The operating margin is -47697.9% (sector: -66.1%). Net profit margin stands at -42998.6%, versus -58.7% for the average Healthcare stock. Revenue growth is running at -64.2% on a trailing basis, compared to 10.6% for the sector. Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

CRNX Debt, Balance Sheet, and Financial Health

Crinetics Pharmaceuticals, Inc. has a debt-to-equity ratio of 14.0%, compared to the Healthcare sector average of 32.0%. The low leverage indicates a conservative balance sheet with significant financial flexibility. The current ratio is 12.32x, indicating strong short-term liquidity. Total debt on the balance sheet is $0. Cash and equivalents stand at $111M.

CRNX has a beta of 1.12, meaning it is roughly in line with the broader market in terms of price volatility. The stability factor score for Crinetics Pharmaceuticals, Inc. is 44/100, reflecting average volatility within the normal range for its sector.

Crinetics Pharmaceuticals, Inc. Revenue and Earnings History — Quarterly Trend

In TTM 2026, Crinetics Pharmaceuticals, Inc. reported revenue of $2M and earnings per share (EPS) of $-4.95. Net income for the quarter was $-419M. Gross margin was 86.0%. Operating income came in at $-471M.

In FY 2025, Crinetics Pharmaceuticals, Inc. reported revenue of $8M and earnings per share (EPS) of $-4.95. Net income for the quarter was $-465M. Gross margin was 86.0%. Revenue grew 640.7% year-over-year compared to FY 2024. Operating income came in at $-517M.

In Q3 2025, Crinetics Pharmaceuticals, Inc. reported revenue of $143,000 and earnings per share (EPS) of $-1.38. Net income for the quarter was $-130M. Operating income came in at $-143M.

In Q2 2025, Crinetics Pharmaceuticals, Inc. reported revenue of $1M and earnings per share (EPS) of $-1.23. Net income for the quarter was $-116M. Revenue grew 158.4% year-over-year compared to Q2 2024. Operating income came in at $-129M.

Over the past 8 quarters, Crinetics Pharmaceuticals, Inc. has demonstrated a growth trajectory, with revenue expanding from $399,000 to $2M. Investors analyzing CRNX stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

CRNX Dividend Yield and Income Analysis

Crinetics Pharmaceuticals, Inc. (CRNX) does not currently pay a dividend. This is common among smaller companies in the Pharmaceutical Products industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

CRNX Momentum and Technical Analysis Profile

Crinetics Pharmaceuticals, Inc. (CRNX) has a momentum factor score of 41/100, reflecting neutral trend characteristics. The stock is neither significantly outperforming nor underperforming the broader market on a momentum basis. The investment factor score is 39/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 55/100 reflects moderate short selling activity.

CRNX vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, Crinetics Pharmaceuticals, Inc. (CRNX) ranks #509 out of 838 stocks based on the Blank Capital composite score. This places CRNX in the lower half of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing CRNX against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full CRNX vs S&P 500 (SPY) comparison to assess how Crinetics Pharmaceuticals, Inc. stacks up against the broader market across all factor dimensions.

CRNX Next Earnings Date

No upcoming earnings date has been announced for Crinetics Pharmaceuticals, Inc. (CRNX) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy CRNX? — Investment Thesis Summary

The quantitative profile for Crinetics Pharmaceuticals, Inc. suggests caution. The quality score of 20/100 flags below-average profitability. The value score of 22/100 indicates premium valuation.

In summary, Crinetics Pharmaceuticals, Inc. (CRNX) earns a Reduce rating with a composite score of 33.3/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on CRNX stock.

Related Resources for CRNX Investors

Explore more research and tools: CRNX vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare CRNX head-to-head with peers: CRNX vs AZN, CRNX vs SLGL, CRNX vs VMD.